TAK 357Alternative Names: TAK-357
Latest Information Update: 13 May 2013
At a glance
- Originator Takeda
- Class Nootropics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 10 May 2013 Discontinued - Phase-I for Alzheimer's disease (PO)
- 31 Jul 2012 Phase-I clinical trials in Alzheimer's disease (PO)